



CIN: L24100GJ1984PLC111413

Reg. Office : 1-5th Floor, Aditraj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad - 380015.

Date: 7th June, 2023

To,
Listing Compliances,
BSE Limited,
P. J. Towers, Fort,
Mumbai - 400001.
Scrip Code: 539938; Scrip Id: MIL

Subject: Public Notice for completion of dispatch of Notice of the 39th Annual General Meeting (AGM) and Annual Report 2022-23.

Dear Sir/Ma'am,

In compliance with Reg. 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of the notice published in English and Gujarati newspapers.

The same will be made available on the Company's website www.medicointercontinental.com.

This is for your information and records.

Thanking You,

FOR MEDICO INTERCONTINENTAL LIMITED

Puneeta Sharma
Company Secretary & Compliance Officer

5G-first key, but 4G phones not off the table, says Samsung's Pullan

JATIN GROVER
New Delhi, June 6

AS SAMSUNG ON Tuesday launched the year's tenth 5G smartphone, the company said its 5G-first strategy is key for growth in the country. But it has not ruled out its focus on smartphone portfolio in other technologies like 4G and below ₹10,000 range.

"Samsung is a full range player, we have got products from ₹7,000 onwards. We have the largest portfolio of 4G phones under ₹13,000. We believe that if we are able to give consumers the right experience at various price points, they will continue to keep upgrading to the next generation (technology) as time passes," Raju Pullan, senior VP, mobile business, Samsung India, told FE.

"We would like to be available across all technologies, but our strategy in India is a 5G-first strategy," Pullan said, adding that the company's financing scheme is one of the key factors that is driving the affordability of 5G smartphones.

Apart from the ten 5G smartphones, Samsung has also launched five 4G ones this year so far. The company's latest phone in the 4G segment was Galaxy A14 4G, whereas in 5G,

There's an installed base of 650 million smartphones in the country. We are seeing a lot of consumers upgrading to 5G.



RAJU PULLAN, SENIOR VICE PRESIDENT, MOBILE BUSINESS, SAMSUNG INDIA

Tailwinds are very strong. It will help us consolidate our leadership across form factors and across our portfolio.

the company on Tuesday launched Galaxy F54 at an introductory price of ₹27,999. When asked about whether the market of 4G phones will diminish completely soon, Pullan said, "As India has the world's largest population, we feel that there is space for all technologies, but contributions can change. Consumers can keep upgrading and that is the route that we are looking at."

In January-March, Samsung maintained its top position in the smartphone market in India with a 20% share. In 5G, too, the company's market share at 24% is the highest among all brands.

"We have seen a very strong double-digit growth, which is helping us consolidate our position. Even in 5G, as per analysts, we have had very strong share gains in April as

well," Pullan said. "Tailwinds are very strong for Samsung, which will help us consolidate our leadership across form factors and across our portfolio," Pullan said, adding that more product launches and financing schemes are key for Samsung's growth.

The starting price of a Samsung 5G phone is around ₹14,000 at present. Last year, the company had launched 13 smartphone models of 5G and this year, it has launched 10 smartphones models in just five months.

Samsung is also strengthening its retail stores presence in the country. The company will open 15 experience stores across Delhi, Mumbai, Bengaluru, Hyderabad, Chennai, Kolkata, Ahmedabad, etc.

"We have to invest in India, so that we are able to give better experience to the consumers and upgrade the lifestyle of consumers in India," Pullan said. In 2022, Samsung's smartphone business grew by over 20%, which was the fastest growth in the last four years. For Samsung, 5G smartphones contributed 61% to its overall smartphone business last year, higher than industry average of 56%, the company had said in January.

Revival plan: Go First told to submit financial details

ROHIT VAID
New Delhi, June 6

THE DIRECTORATE GENERAL of Civil Aviation (DGCA), which is examining Go First's plans to restart operations, has sought financial details relating to its liabilities, contracts as well as availability of working capital, sources told FE.

FE had reported, on June 2, that the interim resolution professional (IRP) of Go First has submitted a six-month revival plan to the DGCA, stating that it's ready to resume operations with 26 operational aircraft and 400 pilots on its rolls.

This is the second instance of DGCA seeking clarifications after the submission of the revival plan, to ascertain whether the airline is in a position to resume operations.

Last week, Go First in its first set of clarifications to the regulator had said that it has

FLIGHT STATUS

Details of Go First's liabilities, contracts and availability of working capital required

IRP has submitted six-month revival plan to the DGCA, stating it's flight-ready

Go First has 26 operational aircraft in its fleet and 400 pilots on its rolls

Flight operations halted till June 9

working capital to pay employees' salaries and charges for fuel, parking, housing and landing charges for a six-month period.

After going through Go First's initial replies on its operational preparedness, DGCA on Tuesday sought more details.

Besides, the regulator has asked the ailing airline whether its lenders are willing to disburse the ₹208 crore that the airline has got under the Emergency Credit Line Guarantee Scheme (ECLGS). The airline is banking on restarting its operations through ₹200 crore and is also trying to raise another ₹200 crore.

The DGCA has also sought details on the constitution of the committee of creditors (CoC) of the airline.

Go First has committed a default of ₹2,660 crore toward aircraft lessors and ₹1,202 crore towards its vendors.

The total liabilities of the airline are ₹11,463 crore, of which bank dues are of ₹6,521 crore. Of this, ₹1,300 crore has been drawn under the government's ECLGS.

The airline had halted flight operations on May 3. The same has been extended June 9.

The main challenge before the airline is to retain its aircraft as lessors have approached the DGCA to deregister 45 of them. Though NCLT and National Company Law Appellate Tribunal have for now rejected the plea, lessors have moved the Delhi High Court. The airline has a fleet strength of 54, of which 28 aircraft are grounded due to engine issues with Pratt & Whitney, and 26 are operational.

In an unrelated development, the low-cost airline on Tuesday paid the May salaries to its pilots.

Enzene's biosimilar cancer drug may be cheaper by around 50%

GEETA NAIR
Pune, June 6

BIOTECHNOLOGY COMPANY ENZENE Biosciences has launched an affordable biosimilar Cetuximab cancer drug. The drug is likely to be cheaper by around 50% and more accessible in the country for the treatment of head, neck and metastatic colorectal cancer.

The key to cost reduction is Enzene's patented continuous manufacturing technology. "Continuous manufacturing can give 10 times higher volumetric productivity cutting down costs of products more

From around ₹1-1.5 lakh, the drug could be offered at ₹50,000 per dose. Marketed by Lupin and Alkem, the cost will be around ₹10,000 per vial

than 50%, which is a huge advantage for biosimilars and it is the reason Enzene is succeeding in this space," Himanshu Gadgil, CEO and whole-time director, Enzene said.

These drugs are expensive and by reducing the cost of manufacturing they could

Gadgil said head and neck cancer presents a significant public health challenge in the country, with a staggering annual incidence of over 1,00,000 new cases and five lakh active cases. This malignancy affects critical regions of the head and neck, including the oral cavity, pharynx, larynx and sinuses. This cancer is more prevalent in the lower socioeconomic strata because of tobacco and alcohol consumption.

Enzene, a biotech subsidiary of Alkem Laboratories based in Pune, is focused on biosimilars, phytopharma, peptide and regenerative business. It has a mammalian manufacturing unit in Chakan, a microbial manufacturing unit in Bhosari and an R&D centre in Pune.

Blue Energy Motors to roll out 2,000 LNG trucks in FY24

GEETA NAIR
Pune, June 6

BLUE ENERGY MOTORS will be selling 2,000 units of its LNG-powered trucks in the country in FY24. CEO Anirudh Bhuwalka said the company has a robust order book and depending on the number of fuel pumps going live, roll out of vehicles from the plant in Chakan, Pune, is likely.

Blue Energy has an installed capacity of 10,000 units per year. There is good interest from all major industrial conglomerates from cement, steel and other sectors to become part of the green trucking revolution, and based on the current interest levels, they were looking at 2,000 units plus rollout for FY24.

The company recently rolled out and invoiced 100 trucks, which have been deployed in the 500 km radius of the three LNG pumps that were functional in Nagpur, Wani and Vadodara.

Ontario to invest ₹750 cr to double Sahyadri beds

GEETA NAIR
Pune, June 6

THE ONTARIO TEACHERS' Pension Plan Board (Ontario Teachers') will invest ₹750 crore to double Sahyadri Hospital chain's hospital beds.

At present, Sahyadri has 1,021 beds with eight hospitals in Maharashtra. It is also among the largest transplant centres in the country with 1,200 cumulative transplants of liver, heart and kidney with plans to add lung and intestine transplants soon. The global investor had acquired an over 90% stake in Sahyadri, the largest hospital chain in Maharashtra, for around ₹2,500-2,700 last year.

The majority stake acquisition came after Everstone Group exited the chain in 2022. Sahyadri was the Canadian investor's first control private equity buyout in India. Ontario Teachers has more than \$3 billion invested in India and opened its office in Mumbai in September 2022.



Sahyadri Hospital chain has 1,021 beds with eight hospitals in Maharashtra

Sahyadri Hospitals will double healthcare delivery infrastructure over the next three to four years and this would include brownfield (200 beds), greenfield (300-500 beds) and M&As (400 in pipeline and 500 beds in future), Abarali Dalal, director & CEO, said.

The hospital chain intends to enter Gujarat and Madhya Pradesh healthcare markets with few deals currently in the pipeline for expansion in the Western part of the country, Dalal said.

AlgoAnalytics, NTT tie up for AI, quantum computing

GEETA NAIR
Pune, June 6

JAPANESE IT COMPANY NTT Data Intellilink has entered into a capital and business alliance agreement with AlgoAnalytics, an Indian AI startup, to expand R&D in large-scale language models, quantum computing and develop digital twin computing.

NTT Data Intellilink, which is a 100% subsidiary of NTT Data Corporation, has been collaborating with AlgoAnalytics on projects prior to the investment, with the latter implementing 50 R&D projects and customer projects for Tokyo-based company over the past five years.

Aniruddha Pant, CEO, AlgoAnalytics, said NTT has picked up a small strategic minority stake in his company but more than the investment it was an opportunity to work with NTT companies and their customers across the globe. They are now part of the NTT family, Pant said. Apart from the investment, work done for NTT would translate into revenues for AlgoAnalytics, he added.

Earlier, R&D money was going into these emerging technologies such as quantum computing but now end users are willing to work with companies like NTT to leverage these technologies. And with NTT having a bunch of customers globally, they are going to be early adopters of the emerging technologies like large language models (LLM), Pant said.

AlgoAnalytics is a small company working in niche areas and emerging technologies that will scale up in the next few years, he said. "Even prior to the widespread popularity of ChatGPT, the data science community was already captivated by the potential of LLMs.

ICICI PRUDENTIAL MUTUAL FUND
TARAKKI KAREENI

ICICI Prudential Asset Management Company Limited
Corporate Identity Number: U99999DL1993PLC054135

Registered Office: 12th Floor, Narain Manzil, 23, Barakhamba Road, New Delhi - 110 001.
Corporate Office: One BKC, 13th Floor, Bandra Kurla Complex, Mumbai - 400 051.
Tel.: +91 22 2652 5000, Fax: +91 22 2652 8100, Website: www.iciciprpfm.com.
Email id: enquiry@iciciprpfm.com

Central Service Office: 2nd Floor, Block B-2, Nirfon Knowledge Park, Western Express Highway, Goregaon (E), Mumbai - 400 063. Tel.: 022 2685 2000 Fax: 022 26868313

Notice to the Investors/Unit holders of ICICI Prudential Fixed Maturity Plan - Series 74 - 9 Years Plan U (the Scheme)

Notice is hereby given that ICICI Prudential Trust Limited, Trustee to ICICI Prudential Mutual Fund has approved the following distribution under Income Distribution cum capital withdrawal option (IDCW option) of the Scheme, subject to availability of distributable surplus on the record date i.e. on June 9, 2023*:

Name of the Scheme/Plans	Quantum of IDCW (₹ per unit) (Face value of ₹ 10/- each) #	NAV as on June 5, 2023 (₹ Per unit)
ICICI Prudential Fixed Maturity Plan - Series 74 - 9 Years Plan U		
IDCW	0.0500	18.8425
Direct Plan - IDCW	0.0500	19.2717

§ The distribution will be subject to the availability of distributable surplus and may be lower depending upon the extent of distributable surplus available on the record date under the IDCW option of the Scheme.

Subject to deduction of applicable statutory levy, if any

* or the immediately following Business Day, if that day is a Non - Business Day.

The distribution with respect to IDCW will be done to all the unit holders/beneficial owners whose names appear in the register of unit holders/Statement of beneficial owners maintained by the Depositories, as applicable under the IDCW option of the Scheme, at the close of business hours on the record date.

It should be noted that pursuant to payment of IDCW, the NAV of the IDCW option of the Scheme would fall to the extent of payout and statutory levy (if applicable).

Suspension of trading of units of ICICI Prudential Fixed Maturity Plan - Series 74 - 9 Years Plan U (FMP - Sr 74 - 9 Yrs PI U):

The units of FMP - Sr 74 - 9 Yrs PI U are listed on NSE. The trading of units of FMP - Sr 74 - 9 Yrs PI U will be suspended on NSE with effect from closing hours of trading of June 8, 2023.

For the purposes of redemption proceeds, the record date shall be June 9, 2023.

For ICICI Prudential Asset Management Company Limited
Place: Mumbai
Date: June 6, 2023
No. 001/06/2023

To know more, call 1800 222 999/1800 200 6666 or visit www.iciciprpfm.com

NSE Disclaimer: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Scheme Information Document (SID) has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the SID. The investors are advised to refer to the SID for the full text of the Disclaimer clause of the NSE.

Investors are requested to periodically review and update their KYC details along with their mobile number and email id.

To increase awareness about Mutual Funds, we regularly conduct Investor Awareness Programs across the country. To know more about it, please visit https://www.iciciprpfm.com or visit AMFI's website https://www.amfiindia.com

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

MEDICO INTERCONTINENTAL LIMITED
CIN: L24100GJ1984PLC111413
Regd. Office: 1-5 th Floor, Adit Raj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad, Gujarat - 380015.
Tel: 079-26742739 Email ID: mail@medicointercontinental.com
Website: www.medicointercontinental.com

NOTICE OF 39th ANNUAL GENERAL MEETING, REMOTE E-VOTING AND BOOK CLOSURE INFORMATION

NOTICE is hereby given that:-

1. The 39th Annual General Meeting of the Members of MEDICO INTERCONTINENTAL LIMITED will be held on Friday, the 30th June, 2023 through Video Conferencing (VC) / Other Audio Visual Means (OAVM) at 12:00 P.M. in compliance with the applicable provisions of the Companies Act, 2013 read with rules issued thereunder, and MCA issued General Circular No. 14/2020 dated 08th April, 2020, MCA General Circular No. 17/2020 dated 13th April, 2020 and MCA General Circular No. 20/2020 dated 05th May, 2020, General Circular No. 02/2021 dated 13th January, 2021, General Circular No. 21/2021 dated 14th December, 2021, General Circular No. 02/2022 dated 5th May, 2022 and General Circular No. 10/2022 dated 28th December, 2022 respectively and circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated 15th January, 2021 and Circular No. SEBI/HO/DDHS/PCIR/2022/0063 dated 13th May, 2022 respectively; issued by the Securities and Exchange Board of India, to transact the business as set forth in the notice of the Annual General Meeting dated 29th May, 2023.

2. Electronic copies of the Notice of the AGM and Annual Report for fiscal 2023 have been sent to all the members whose email IDs are registered with the Company's Depository Participant(s). These documents are also available on the website of the Company at www.medicointercontinental.com. The dispatch of notice of AGM through electronic mode has been completed on 6th June, 2023.

3. In terms of and in compliance with provisions of section 108 of the Act read with Rule 20 of Companies (Management and Administration) Rules, 2014 as amended from time to time and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is providing the "remote e-voting" and "e-voting during the AGM", facility to members to cast their vote electronically on all the resolutions set forth in the Notice of the 39th AGM through electronic voting system of Central Depository Services Limited ("CDSL"). The cut-off date for determining the eligibility to vote by electronic means through "remote e-voting" or "e-voting at the AGM" is 23rd June, 2023.

4. All the members are informed that:

a. The business set forth in the notice of the AGM may be transacted through voting by electronic means;

b. The remote e-voting shall commence from June 27, 2023 (9:00 A.M.)

c. The remote e-voting shall end on June 29, 2023 (5:00 P.M.)

d. The cut-off date for determining the eligibility to vote by electronic means or at the AGM is June 23, 2023

e. E-voting by electronic mode shall not be allowed beyond 5:00 P.M. on June 29, 2023;

f. Any person who acquires shares of the Company and becomes a member of the Company after dispatch of the Notice of the AGM and holding shares as on the cut-off date i.e., June 23, 2023 may vote in the Annual General Meeting and may obtain the login ID and password by sending a request at helpdesk.evoting@cdsindia.com. For the process and manner of E-voting, Members may go through the instructions mentioned in Note No. 32 of the Notice of 39th AGM.

g. Members may note that: i) The remote e-voting module shall be disabled by CDSL beyond 5:00 P.M. on June 29, 2023 and once the vote on a resolution is cast by the member, the member shall not be allowed to change it subsequently; ii) The facility of e-voting shall be made available at the AGM; iii) The members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again; and iv) Only persons whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail facility of remote e-voting or e-voting at the AGM;

h. The Notice of the AGM is available on the Company's website www.medicointercontinental.com and also on the CDSL's website www.evotingindia.com;

i. In case of any queries/grievances connected with e-voting, please contact: Mr. Rakesh Dalvi, Manager, CDSL, A wing, 25th Floor, Marathon Futurex, Mafatal Mill Compounds, N M Joshi Marg, Lower Pareil East, Mumbai - 400 013 or send an email to helpdesk.evoting@cdsindia.com or call 022-23058542/43.

5. The Register of Members and Share Transfer Books of the Company will remain closed from 24th June, 2023 to 30th June, 2023 (both days inclusive) to determine the names of members, who will be entitled to receive the final dividend of Rs. 0.10 per equity share for the year ended 31st March, 2023.

For MEDICO INTERCONTINENTAL LIMITED
Place: Ahmedabad
Date: 6th June, 2023

Sd/-
SAMIR SHAH
MANAGING DIRECTOR

TATA TATA POWER

THE TATA POWER COMPANY LIMITED
Registered Office: Bombay House, 24, Horni Mody Street, Mumbai 400 001.
Tel: 91 22 6665 8282 CIN: L28920MH1919PLC000567
Email: tatapower@tatapower.com Website: www.tatapower.com

NOTICE OF RECORD DATE

NOTICE is hereby given pursuant to Section 91 of the Companies Act, 2013 that:

i. Wednesday, July 5, 2023 has been fixed as the Record Date for the purpose of payment of Annual interest on the 3,500 - 8.55% Unsecured Redeemable Non-Convertible Debentures aggregating a cumulative face value of ₹10,00,00,000 and the redemption proceeds of these Debentures aggregating ₹ 3,50,00,00,000 due on July 20, 2023.

ii. Thursday, July 6, 2023 has been fixed as the Record Date for the purpose of payment of Annual interest on the 100 - 9.15% Secured Redeemable Non-Convertible Debentures aggregating a cumulative face value of ₹20,00,00,000 each (STRPP M to O) and the redemption proceeds of the Separately Transferable Redeemable Principal Part M of these Debentures (INE245A07242), aggregating ₹20,00,00,000, both due on July 21, 2023.

For The Tata Power Company Limited
Sd/-
H. M. Mistry
Company Secretary

Place: Mumbai
Date: June 5, 2023

APEX CAPITAL AND FINANCE LIMITED
(Formerly Apex Home Finance Limited)
CIN: L65910DL1985PLC021241
Regd. Office: L-3, Green Park Extension, New Delhi - 110016
Email: contact@apexfinancials.in; Website: www.apexfinancials.in; Tele-Fax: +91 11 40348775

EXTRACTS OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023
(Rs. in Lacs)

Sl. No.	PARTICULARS	Quarter Ended		Year Ended	
		31/03/2023 (Audited)	31/03/2022 (Audited)	31/03/2023 (Audited)	31/03/2022 (Audited)
1	Total Income from operations	150.54	126.30	511.13	510.79
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	32.29	15.81	87.90	47.60
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	32.29	15.81	87.90	47.60
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	23.17	11.77	63.47	34.90
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	23.17	11.77	63.47	34.90
6	Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	592.00	592.00	592.00	592.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	2,034.86	1,971.38
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinuing operations)				
	Basic (Rs.)	0.39	0.20	1.07	0.59
	Diluted (Rs.)	0.39	0.20	1.07	0.59

NOTES:

1. The above audited financial results for the quarter and year ended March 31, 2023 have been reviewed and recommended by the Audit Committee in its meeting held on 05.06.2023 and thereafter approved and taken on record by the Board of Directors in its meeting held on 05.06.2023. The Statutory Auditors of the Company have carried out a statutory audit of the aforesaid financial results.

2. The above is an extract of the detailed format of quarterly & yearly Financial Results filed with BSE Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results for the quarter and year ended March 31, 2023 are available at the Stock Exchange Website at www.bseindia.com and on the Company's Website at www.apexfinancials.in

By the Order of the Board
For Apex Capital and Finance Limited
Sd/-
(Shekhar Singh)
Managing Director
DIN: 00039567

Date: 05.06.2023
Place: New Delhi

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE STOCK EXCHANGES IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL DISCLOSURE REQUIREMENTS) REGULATIONS, 2016, AS AMENDED.

PUBLIC ANNOUNCEMENT



VALIANT LABORATORIES LIMITED

Our Company was originally formed as a partnership firm under the name and style of M/s. Bharat Chemicals pursuant to the deed of partnership dated October 17, 1980, and amended and restated from time to time. Subsequently, the partnership firm, M/s. Bharat Chemicals was converted into a public limited company under the provisions of the Companies Act with the name "Valiant Laboratories Limited" pursuant to certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies, please refer to the section titled "History and Certain Corporate Matters" beginning on page 183 of the Draft Red Herring Prospectus dated June 05, 2023 ("DRHP").

Registered Office: 104, Udyog Kishore, Mulund Goregaon Link Road, Mulund West, Mumbai- 400080, Maharashtra. Telephone: +91 2249712001. Website: www.valiantlabs.in

Contact Person: Saloni Mehta, Company Secretary and Compliance Officer. E-mail: complianceofficer@valiantlabs.in. Corporate Identity Number: U24299MH2021PLC359504

PROMOTERS OF OUR COMPANY: SHANTILAL SHIVJI VORA AND DHANVALLABH VENTURES LLP

INITIAL PUBLIC OFFER OF UP TO 11,55,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF VALIANT LABORATORIES LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [x] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [y] PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹ [x+y] MILLION ("ISSUE"). THE ISSUE SHALL CONSTITUTE [z] % OF THE FULLY-DILUTED POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF EQUITY SHARES IS ₹ 10 EACH. THE ISSUE PRICE IS [x+y] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER AND WILL BE ADVERTISED IN ALL EDITIONS OF [z] [+], AND ALL EDITIONS OF [z] [+], WHICH ARE WIDELY CIRCULATED ENGLISH DAILY NEWSPAPER AND HINDI DAILY NEWSPAPER, AND [z] EDITIONS OF THE MANGALM REGIONAL NEWSPAPER (MANGALM BEING THE REGIONAL LANGUAGE OF MAHARASHTRA, WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST 7 WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO BE MADE AVAILABLE TO BSE ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE" AND TOGETHER WITH BSE AND THE "STOCK EXCHANGES") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2016, AS AMENDED ("SEBI ICDR REGULATIONS").

In case of any revision to the Price Band, the Bid/Issue Period will be extended by at least the third Working Days following such revision of the Price Band, subject to the Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, in consultation with the Book Running Lead Manager, may extend the Bid/Issue Period for a maximum of three Working Days. In case of any such extension, the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the Book Running Lead Manager and at the terminals of the Syndicate Members and by intimation to Self-Certified Broking Banks ("SCBBs"), other Designated Intermediaries and the Sponsor Bank, as applicable.

The issue is being made in terms of Rule 19(2)(b) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2016, as amended ("SEBI ICDR Regulations"). The issue is being made through the Syndicate Process in accordance with Regulation 8(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") provided that our Company, in consultation with the Book Running Lead Manager, may allocate up to 60% of the QIB Portion to Anchor Investors and the balance of such allocation will be on a discretionary basis by our Company, in consultation with the SEBI ICDR Regulations. The Anchor Investor Portion ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid bids being received from the domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Price"), in the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and any remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs including Mutual Funds, subject to valid bids being received at or above the Issue Price. Further, not less than 15% of the Issue shall be available for allocation to NII's ("Non-Institutional Category") of which one-third of the Non-Institutional Category shall be available for allocation to Bidders with an application size of more than ₹ 20 million and up to ₹ 1.00 million and two-thirds of the Non-Institutional Category shall be available for allocation to Bidders with an application size of more than ₹ 1.00 million and up to ₹ 20 million in either of these two sub-categories of Non-Institutional Category may be allocated to Bidders in the other sub-category of Non-Institutional Category in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price. Further, not less than 35% of the Issue shall be available for allocation to RII's ("Retail Investor Category"), in accordance with the SEBI ICDR Regulations, subject to valid bids being received from them at or above the Issue Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Issue only through the Application Supported by Blocked Amount ("ASBA") process and shall provide details of their respective bank account (including IPI ID (defined hereinafter) in case of IPI Bidders (defined hereinafter) in which the Bid Amount will be blocked by the Self-Certified Syndicate Banks ("SCSBs") or the Sponsor Banks, as the case may be. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. For details, see "Issue Procedure" on page 357 of the DRHP.

This public announcement is being made in compliance with the provisions of regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the DRHP dated June 05, 2023 with the Securities and Exchange Board of India ("SEBI") on June 05, 2023 pursuant to Regulation 26(1) of the SEBI ICDR Regulations. The DRHP filed with SEBI shall be made public and available, if any, for a period of at least 21 (twenty one) days from the date of such filing, by hosting it on the websites of SEBI at www.sebiindia.com and our Company at www.valiantlabs.in, and the Stock Exchanges where the Equity Shares are proposed to be listed, i.e. BSE at www.bseindia.com and NSE at www.nseindia.com. Our Company hereby invites the public to give their comments on the DRHP filed with SEBI in respect of discussions made in the DRHP. The public is requested to send a copy of the comments sent to SEBI, to the Company Secretary, Saloni Mehta, at the registered office of the Company at www.valiantlabs.in. All comments sent must be received by our Company or the SEBI in relation to the Issue on or before 5 p.m. on the 21st day from the aforementioned date of filing of the DRHP with SEBI.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Issue unless they are able to take the risk of their own investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, Bidders must rely on their own examination of the Company and the Issue, including the risks involved. The issue of Equity Shares in the Issue has neither been recommended, nor approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the DRHP.

Specific attention of the Bidders is invited to "Risk Factors" beginning on page 38 of the DRHP. Any decision to invest in the equity shares described in the DRHP may be made after a Red Herring Prospectus ("RHP") has been registered with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when offered through the RHP, are proposed to be listed on Stock Exchanges.

The liability of the members of our Company is limited by shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see "History and Certain Corporate Matters" beginning on page 183 of the DRHP. For details of the share capital and capital structure of our Company and the names of the signatories of the Memorandum of Association and a list of members of our Company subscribed by them, please see "Capital Structure" beginning on page 94 of the DRHP.

BOOK RUNNING LEAD MANAGER REGISTRAR TO THE ISSUE LINK Intime LINK INTIME INDIA PRIVATE LIMITED C-101, 247 Park, 1st Floor, L.S. Marg, Vikhroli West Mumbai 400 063, Maharashtra. Telephone: +91 8108119640. Fax: +91 22 4918660. Email: info@linkintime.com. Website: www.linkintime.com. For Valiant Laboratories Limited On behalf of Board of Directors Sd/ Company Secretary and Compliance Officer

UNISTONE CAPITAL PRIVATE LIMITED A-315, Dynasty Tower, 1st Floor, Connaught Place, New Delhi, India. Telephone: +91 9820057533. Email: info@unistonecapital.com. Investor grievance email: compliance@unistonecapital.com. Contact Person: Mr. Rishabh Parekh. Website: www.unistonecapital.com. SEBI registration number: INM000012449. CIN: U65999MH2019PTC33050. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed in the DRHP.

Place: Mumbai, Maharashtra Date: June 06, 2023 VALIANT LABORATORIES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the DRHP dated June 05, 2023 with SEBI on June 05, 2023. The DRHP shall be available on the website of SEBI at www.sebiindia.com and our Company at www.valiantlabs.in. The public is requested to send a copy of the comments sent to SEBI, to the Company Secretary, Saloni Mehta, at the registered office of the Company at www.valiantlabs.in. All comments sent must be received by our Company or the SEBI in relation to the Issue on or before 5 p.m. on the 21st day from the aforementioned date of filing of the DRHP with SEBI.

The Equity Shares offered have not been and will not be registered under the U.S. Securities Act, 1933, as amended ("U.S. Securities Act") or any other applicable laws in the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered outside the United States in reliance on transactions as defined in and in reliance on regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where these offers and sales are made. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and will not be issued or sold, and bids may not be made by persons in any such jurisdiction, except in compliance with applicable laws of such jurisdiction.

Table with 5 columns: Sr. No., Particulars, Quarter ended 31.03.23, Quarter ended 31.03.22, Year ended 2023, Year ended 2022. Includes Total Income from Operations, Net Profit, Corporate Income Tax, etc.

Notes: a) The above is an extract of the detailed format of annual financial results filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements), 2015 ("Listing Regulations"). The full format of the annual financial results are available on the website of BSE Ltd. (www.bseindia.com) and Company's website (www.valiantlabs.in). b) In the absence of audited profits, the Company has not created Debenture Redemption Reserve during the period. c) In the absence of revenue, Debt Service Coverage Ratio and interest service coverage ratio have not been reported. d) Figures for previous year have been regrouped, wherever necessary, for the purpose of comparison.

અમદાવાદ, મુંબઈ, દે. ૦૬.૦૬.૨૦૨૩ શ્રેયનાસ્તિયલ એક્સ્પ્રેસ ૭

SMFG Grihshakti SMFG INDIA HOME FINANCE COMPANY LIMITED (Formerly Fullerton India Home Finance Co., Ltd.) Regd Office: Mugh Towers, 3rd floor, Old No. 307, New No. 165, Poonamallee High Road, Madhavaram, Chennai - 600095. Toll-free No: 1800 162 1003

PUBLIC NOTICE Notice is hereby given to all our customers, partners and public at large that the name of the company "Fullerton India Home Finance Company Limited" (CIN: U659222N2101CO167972) has been changed to "SMFG India Home Finance Company Limited" (CIN: U659222N2101CO167972) with effect from 15.05.2023.

For SMFG INDIA HOME FINANCE COMPANY LIMITED (Formerly Fullerton India Home Finance Co. Ltd.) Sd/ Authorized Signatory

OBEROO OBEROI REALTY LIMITED Regd. Office: Corridor, 7 Floor, International Business Park, Oberoi Garden City, Old Western Express Highway, Goregaon (E), Mumbai - 400033. Website: www.oberoorealty.com. Tel: 91 22 6977 3333

NOTICE Annual General Meeting and Annual Report The 25th Annual General Meeting of Members ("AGM") of the Company to transact the business as set forth in the notice of the meeting ("Notice") will be held on Wednesday, June 28, 2023 at 3:00 p.m. through video conference and/or audio tele-conference ("VCO") without the physical presence of the Members of the Company, in compliance with the applicable provisions of Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with General Circular No. 14/2020, 17/2020, 20/2020 and 19/2022 issued by Ministry of Corporate Affairs, and Circular No. SEBI/IO/CD/CMD/CI/RP/2022/022 and SEBI/IO/CP/DO/2022/0234 issued by Securities and Exchange Board of India (collectively, the "said Circulars").

Members who have not registered their email addresses for receiving documents in electronic form are requested to register their email addresses; and such members can obtain login credentials for e-voting by sending following details to cs@oberoorealty.com: (A) their folio/ demat account number, (B) their Email id, and (C) scanned copy of their (i) share certificate (Front & back) or client master or consolidated statement, (ii) PAN card (self attested), (iii) Aadhar (self attested). In respect of shares held in physical form, the Company will update the email address based on the information. Members holding shares in demat mode are requested to update their email address with their depository participant. Members are requested to keep their email id updated in their demat account, as the case may be.

Members desirous of obtaining any information concerning the accounts and operations are requested to address their queries at cs@oberoorealty.com at least 7 working days prior to the AGM, to enable the Company to suitably reply to such queries at the AGM by email. E-voting Information In terms of Section 108 of the Companies Act, 2013, read with Rules thereto, Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the said Circulars, the Company is providing e-voting facility to its members to cast their vote by electronic means through the AGM. The cut-off date for registration on the AGM, on all the resolutions set forth in the Notice. The Company has engaged services of Central Depository Services (India) Limited (CDSL), for providing e-voting facility. Kindly refer the Notice regarding instructions on e-voting. The Notice will also be available on the e-voting website of CDSL, www.evotingindia.com.

Remote e-voting shall commence from June 24, 2023 (9:00 AM) and ends on June 27, 2023 (5:00 PM). The remote e-voting module shall be disabled by CDSL after 5:00 PM on June 27, 2023. The cut-off date for determining the eligibility to vote is June 21, 2023 and the cut-off date for determining the eligibility of the Company (in physical/dematized form) on the cut-off date shall be entitled to the facility of e-voting. Any person who acquires shares of the Company and becomes a Member of the Company after the dispatch of the Notice and holds shares on the cut-off date of June 21, 2023, should follow the instructions given in the Notice to obtain a login ID and password for e-voting. Members who have not voted through Remote e-voting facility, will be permitted to vote through e-voting at the AGM. The Members who have already casted their votes through Remote e-voting may attend the AGM through VCO shall not be entitled to cast their vote during the AGM.

In case you have any queries or issues or seek assistance w.r.t. VCO facility before or during the meeting, or regarding CDSL e-voting system, you can write an email to helpdesk.evoting@csindia.com or call CDSL at 1800 22 2233. Alternatively, the e-voting related grievances may be addressed to Mr. Rakesh Dair, Senior Manager, Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futura, Malafiala Mill Compound, N.M. Joshi Marg, Lower Park, Mumbai-400013 or by email to helpdesk.evoting@csindia.com or call CDSL at 1800 22 2233.

Record Date: Also, notice is hereby given that the record date for the purpose of payment of dividend on equity shares for the year ended March 31, 2023 is June 21, 2023. Accordingly, the dividend will be paid to the members whose names are recorded in the Register of Members of the Company as on the said date. Annual General Meeting: The Annual General Meeting, would be paid to those members whose name appears in the Register of Members at the end of the day on June 21, 2023.

Date: June 23, 2023 For OBEROI REALTY LIMITED Bhaskar Khinrao Company Secretary

NMDC Limited (A Government of India Enterprise) PELLET PLANT DONMALAI Donmalai Township, 5818, Old, Banank, Karnataka, Phone: 98395 274613 GST No: 29AAAN275525220. EOI NO-DN/IMP/PT/EOI-12023 Date: 07.06.2023 EXPRESSION OF INTEREST NOTICE (EOI) Item Description: THE WORK OF INSTALLATION OF DRY CRUSHING, SCREENING AND CONVEYOR SYSTEM FOR SIZE REDUCTION OF IRON ORE FINES (IOF) FROM -10MM TO -5MM FOR AN ANNUAL QUANTITY OF 6 LAKH TONNES (Minimum) ON A BUILT OWN OPERATE MODEL BASIS AT THE BENEFICIARY PLANT OF THE PELLET PLANT-DONMALAI. Prospective Bidders having relevant experience of providing services of similar nature are invited to submit their application by June 28, 2023 to be followed by participation in discussion/Presentation meeting at Pellet Plant, NMDC Ltd. Donmalai. Please refer to the EOI Document hosted on the website http://www.nmco.com/nmcdonmalai/offerlist.aspx and also in CPP Portal for further details. For further information, Project Manager, Pellet Plant Donmalai, Donmalai Township, Dist. Bellary, Karnataka-583118 or at kchandraasekh@nmco.com. For and on behalf of NMDC Ltd. Project Manager, Pellet Plant

SMFG India Credit Company Limited (Formerly Fullerton India Credit Co. Ltd.) Regd Office: Mugh Towers, 3rd floor, Old No. 307, New No. 165, Poonamallee High Road, Madhavaram, Chennai - 600095. Toll-free No: 1800 160 8001

PUBLIC NOTICE Notice is hereby given to all our customers, partners and public at large that the name of the company "Fullerton India Credit Company Limited" (CIN: U651911N1994PLG79235) has been changed to "SMFG India Credit Company Limited" (CIN: U651911N1994PLG79235) with effect from 11.05.2023.

For SMFG INDIA CREDIT COMPANY LIMITED (Formerly Fullerton India Credit Co. Ltd.) Sd/ Authorized Signatory

OPTEMUS INFRACON LIMITED CIN: L64200G1939PLC50406 Registered Office: K-26, Second Floor, Light Nagar - II, New Delhi-110024 Corporate Office: 10th Floor, Sector 63, Noida - 201301. Website: www.opitemus.com | Email: info@opitemus.com | Ph: 011 29849096

Notice is hereby given that the following Shares Certificate have been reported as lost/duplicate and the holder of such Share Certificate has applied to Company in form of Duplicate Share Certificates. S. No. Folio No. Shareholder's Name of Certificate (No.) Distinctive No. No. of Shares

Table with 5 columns: S. No., Folio No., Shareholder's Name, No. of Certificate (No.), Distinctive No., No. of Shares. Includes entries for Vinod Kant, Anand Kumar, etc.

Any person(s) who has any claim(s) in respect of the above share certificate(s) should lodge such claim(s) with the Company "Opitemus Infracon Limited" at the Corporate Office, situated at K-26, Sector 63, Noida - 201301 or write at opitemus@opitemus.com within 15 days of the publication of the NOTICE. After this date claim will be entertained and the Company will proceed to issue the Duplicate Share Certificates. FOR OPTEMUS INFRACON LIMITED Vikas Chandra Company Secretary & Compliance Officer Date: 06th June, 2023 Place: Noida

MEDICO INTERCONTINENTAL LIMITED CIN: L24100G1984PLC111413 Regd. Office: 1-5 H Floor, Adli Raj Arcoade, Nr. Karma Shreshtha Tower, Ahmedabad, Gujarat. Telephone: 079-26724730. Email: info@medicointercontinental.com. Website: www.medicointercontinental.com

NOTICE OF 39th ANNUAL GENERAL MEETING, REMOTE E-VOTING AND BOOK CLOSURE INFORMATION NOTICE is hereby given that - 1. The 39th Annual General Meeting of the Members of MEDICO INTERCONTINENTAL LIMITED will be held on Wednesday, the 30th June 2023 through Video Conferencing (VCO) / Other Audio Visual Means (OAVM) at 12:00 PM in compliance with the applicable provisions of the Companies Act, 2013 read with Rules 19(2)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the said Circulars, the Company is providing e-voting facility to its members to cast their vote by electronic means through the AGM. The cut-off date for registration on the AGM, on all the resolutions set forth in the Notice of the 39th AGM through electronic voting system of Central Depository Services Limited ("CDSL"). The cut-off date for determining the eligibility to vote by electronic means through "remote voting" or e-voting at the AGM is 23rd June, 2023.

a) The business set forth in the notice of the AGM may be transacted through e-voting. b) The remote e-voting shall commence from June 23, 2023 (9:00 AM). c) The remote e-voting shall end on June 29, 2023 (5:00 PM). d) The cut-off date for determining the eligibility to vote by electronic means or at the AGM is June 23, 2023. e) E-voting by electronic mode shall not be allowed beyond 5:00 PM on June 23, 2023.

f. Any person who acquires shares of the Company and becomes a member of the Company after the dispatch of the Notice of the AGM and holds shares on the cut-off date of June 21, 2023, should follow the instructions given in the Notice to obtain a login ID and password for e-voting. Members who have not voted through Remote e-voting facility, will be permitted to vote through e-voting at the AGM. The Members who have already casted their votes through Remote e-voting may attend the AGM through VCO shall not be entitled to cast their vote during the AGM.

Record Date: Also, notice is hereby given that the record date for the purpose of payment of dividend on equity shares for the year ended March 31, 2023 is June 21, 2023. Accordingly, the dividend will be paid to the members whose names are recorded in the Register of Members of the Company as on the said date. Annual General Meeting: The Annual General Meeting, would be paid to those members whose name appears in the Register of Members at the end of the day on June 21, 2023.

Date: June 23, 2023 For MEDICO INTERCONTINENTAL LIMITED Bhaskar Khinrao Company Secretary

OPTEMUS INFRACON LIMITED CIN: L64200G1939PLC50406 Registered Office: K-26, Second Floor, Light Nagar - II, New Delhi-110024 Corporate Office: 10th Floor, Sector 63, Noida - 201301. Website: www.opitemus.com | Email: info@opitemus.com | Ph: 011 29849096

Notice is hereby given that the following Shares Certificate have been reported as lost/duplicate and the holder of such Share Certificate has applied to Company in form of Duplicate Share Certificates. S. No. Folio No. Shareholder's Name of Certificate (No.) Distinctive No. No. of Shares

Table with 5 columns: S. No., Folio No., Shareholder's Name, No. of Certificate (No.), Distinctive No., No. of Shares. Includes entries for Vinod Kant, Anand Kumar, etc.

पंजाब नैशनल बैंक Punjab National Bank

पंजाब नैशनल बैंक - १३ (ए) (पंजाब रिजर्व बैंक में) भारतीय रिजर्व बैंक के अधीन आने वाले बैंक का अधिकांश हिस्सा रिजर्व बैंक में है।

आपकी बैंक खाता पंजीकरण प्रक्रिया में आने वाले बैंक का अधिकांश हिस्सा रिजर्व बैंक में है। भारतीय रिजर्व बैंक के अधीन आने वाले बैंक का अधिकांश हिस्सा रिजर्व बैंक में है।

Table with 4 columns: Sr. No., Particulars, Quarter ended 31.03.23, Quarter ended 31.03.22, Year ended 2023, Year ended 2022. Includes Total Income from Operations, Net Profit, Corporate Income Tax, etc.

Notes: a) The above is an extract of the detailed format of annual financial results filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements), 2015 ("Listing Regulations"). The full format of the annual financial results are available on the website of BSE Ltd. (www.bseindia.com) and Company's website (www.valiantlabs.in). b) In the absence of audited profits, the Company has not created Debenture Redemption Reserve during the period. c) In the absence of revenue, Debt Service Coverage Ratio and interest service coverage ratio have not been reported. d) Figures for previous year have been regrouped, wherever necessary, for the purpose of comparison.

For and on behalf of the Board Sd/ Arvind Kumar Mishra Director Date: 05 June, 2023 DIN: 08250280